Previous 10 | Next 10 |
SAN FRANCISCO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the initiation of a Pha...
The following slide deck was published by 89bio, Inc. in conjunction with this Read more ...
89bio (NASDAQ: ETNB ) : Q2 GAAP EPS of -$0.85 misses by $0.05 . More news on: 89bio, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
- Topline results from BIO89-100’s Phase 1b/2a NASH trial are expected in Late Q3 to Early Q4 - - BIO89-100’s Phase 2 SHTG trial is expected to be initiated in Q3 - SAN FRANCISCO, Aug. 13, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharma...
SAN FRANCISCO, July 13, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, announced the closing of its upsize...
MOGU (NYSE: MOGU ) -14% . More news on: MOGU Inc., Ascena Retail Group, Inc., Fuel Tech, Inc., Stocks on the move, , Read more ...
89bio (NASDAQ: ETNB ) has priced its upsized public offering of 2,649,600 common shares (from 2.2M shares) at $27.50/share, for expected gross proceeds of ~$72.9M. More news on: 89bio, Inc., Healthcare stocks news, , Read more ...
SAN FRANCISCO, July 07, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the pricing of an u...
89bio (NASDAQ: ETNB ) to issue 2.2M common shares, with underwriters' over-allotment option of an additional 330K shares. More news on: 89bio, Inc., Healthcare stocks news, , Read more ...
SAN FRANCISCO, July 06, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that it has commenced an...
News, Short Squeeze, Breakout and More Instantly...
2024-06-21 09:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN FRANCISCO, May 22, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that data from the 48-week exten...
—With the initiation of ENLIGHTEN-Cirrhosis, pegozafermin is the first FGF21 analog to enter a Phase 3 trial in MASH patients with compensated cirrhosis (F4)— —Regression of fibrosis by histology at month 24 will serve as the basis for potential accelerated approval...